Biotechnology
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of itsGenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference inS...
2024-11-21 23:46
950
I-Mab to Participate at the Piper Sandler Healthcare Conference
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treat...
2024-11-21 20:00
978
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024
SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will part...
2024-11-21 18:00
901
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthr...
2024-11-21 15:09
1380
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation
This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswi...
2024-11-21 13:01
1024
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...
2024-11-20 22:00
1459
CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships
FRANKFURT, Germany, Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held inFrankfurt, Germany. ...
2024-11-20 21:00
876
2024 Global Healthy Longevity Conference Successfully Held
SHENZHEN, China, Nov. 20, 2024 /PRNewswire/ -- The 2024 Global Healthy Longevity Conference took place successfully in Shenzhen from 15-17 November. Under the theme "The Healthy Longevity Era: Technology-driven Anti-Aging," the conference combined exhibitions and forum presentations to explore ke...
2024-11-20 19:13
1066
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...
2024-11-20 07:20
1192
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...
2024-11-19 21:26
1051
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
920
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...
2024-11-19 08:00
1529
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...
2024-11-18 22:00
1513
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...
2024-11-18 21:50
1225
FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection
BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...
2024-11-18 18:40
985
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd.
2024-11-18 08:00
998
Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth
- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...
2024-11-15 22:00
1502
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...
2024-11-15 20:00
1223
Angel Yeast Turns Automation into Opportunity, Ensuring No Job Losses
YICHANG, China, Nov. 15, 2024 /PRNewswire/ -- Angel Yeast has taken a significant step towards modernization and sustainability by automating its packaging line while ensuring no layoffs for its employees. In 2024, with the completion of the intelligent transformation of its packaging workshop, t...
2024-11-15 20:00
1211
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-11-15 09:55
1169
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
